(CRVO) CervoMed - Ratings and Ratios

CervoMed Inc. (NASDAQ:CRVO) is a biotechnology company dedicated to developing innovative treatments for age-related neurological disorders. The companys lead drug candidate, neflamapimod, is an orally administered small molecule that can penetrate the brain. It is currently in clinical trials for the treatment of dementia with Lewy bodies (DLB), Alzheimers disease, frontotemporal dementia, and ischemic stroke recovery. Additionally, CervoMed is developing EIP200, a compound in preclinical trials targeting central nervous system disorders. Founded in 2010, the company is headquartered in Boston, Massachusetts, and focuses on advancing small molecule therapies for brain-related diseases.

From a technical perspective, CervoMeds stock (CRVO) has shown a 20-day average volume of 59,768 shares, with a last price of $2.21. The stocks 20-day and 50-day simple moving averages (SMA) are both around $2.21 and $2.23, respectively, while the 200-day SMA is significantly higher at $11.25. This indicates a potential recent decline in stock value. The Average True Range (ATR) of 0.14 suggests low volatility in recent trading activity.

On the fundamental side, CervoMed has a market capitalization of $17.75 million USD. The price-to-book (P/B) ratio is 0.39, indicating that the stock may be undervalued relative to its book value. The price-to-sales (P/S) ratio is 1.76, which is moderate. However, the return on equity (RoE) is -26.18%, reflecting significant losses. The lack of earnings is evident from the P/E and forward P/E ratios, both of which are zero.

Based on the provided technical and fundamental data, the 3-month forecast for CervoMed Inc. (CRVO) suggests a potentially stable but challenging period. The stocks low average volume and negative RoE may indicate limited investor confidence and liquidity. While the low ATR suggests reduced volatility, the significant gap between the 200-day SMA and current price could signal undervaluation. Overall, the stock may experience sideways movement or a slight decline in the near term.